This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GE HealthCare (GEHC) AI Model to Predict Immunotherapy Response
by Zacks Equity Research
GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.
Momentum Monday: Inflation Data in Focus this Week
by Ethan Feller
Want to start the week ahead of the pack? Check out Momentum Mondays
Thermo Fisher (TMO) Unveils CorEvitas Clinical Registry in GPP
by Zacks Equity Research
Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.
Cardinal Health (CAH) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Fresenius Medical (FMS) Divests Assets to Optimize Portfolio
by Zacks Equity Research
Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.
Zacks.com featured highlights include Cardinal Health, Toll Brothers, Iron Mountain, NetApp and Ralph Lauren
by Zacks Equity Research
Cardinal Health, Toll Brothers, Iron Mountain, NetApp and Ralph Lauren are part of the Zacks Screen of the Week article.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
Medtronic's (MDT) MiniMed 780G System Study Data Favorable
by Zacks Equity Research
Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Zimmer Biomet (ZBH) Rides on ROSA Uptake, Favorable Trend
by Zacks Equity Research
Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.
Labcorp (LH) Introduces Weight Loss Management Portfolio
by Zacks Equity Research
Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
by Zacks Equity Research
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System
by Zacks Equity Research
DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
by Zacks Equity Research
Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.
Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone
by Zacks Equity Research
Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.
5 Stocks Favored by Brokers Amid Current Uncertainty
by Maharathi Basu
We believe that stocks like General Motors (GM), Cardinal Health (CAH), Deutsche Bank (DB), Group 1 (GPI) and Centene (CNC) should be on an investor's watchlist.
5 Dividend Stocks With High Growth Prospects
by Sweta Killa
Cardinal Health (CAH), Toll Brothers (TOL), Iron Mountain (IRM), NetApp (NTAP) and Ralph Lauren (RL) have strong dividend growth prospects.
Davita (DVA) Shares Gain This Week: Will the Rally Continue?
by Zacks Equity Research
DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.
DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?
by Zacks Equity Research
A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.
Best Growth Stocks to Buy for March 8th
by Zacks Equity Research
POWL, CAH and PAGS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 8, 2023.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.
Abbott (ABT) to Reduce Childhood Malnutrition With New Pact
by Zacks Equity Research
Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.
Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales
by Zacks Equity Research
Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.
QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.